Shares of OncoCyte Corp (NYSEAMERICAN:OCX) fell 1.8% on Monday . The company traded as low as $3.81 and last traded at $3.93. 2,900 shares traded hands during trading, a decline of 100% from the average session volume of 2,432,945 shares. The stock had previously closed at $4.00.

Several equities analysts have weighed in on the company. Zacks Investment Research downgraded OncoCyte from a “buy” rating to a “hold” rating in a research report on Saturday, January 26th. began coverage on OncoCyte in a report on Monday, October 29th. They issued a “positive” rating on the stock. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a report on Tuesday, January 29th. Finally, Lake Street Capital reiterated a “buy” rating on shares of OncoCyte in a report on Wednesday, December 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $5.33.

OncoCyte (NYSEAMERICAN:OCX) last announced its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02.

A hedge fund recently raised its stake in OncoCyte stock. Vanguard Group Inc boosted its position in OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 410,275 shares of the biotechnology company’s stock after buying an additional 15,115 shares during the quarter. Vanguard Group Inc owned approximately 1.01% of OncoCyte worth $1,026,000 at the end of the most recent quarter.

ILLEGAL ACTIVITY WARNING: “OncoCyte (OCX) Shares Down 1.8%” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at

OncoCyte Company Profile (NYSEAMERICAN:OCX)

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Featured Article: Stock Split

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with's FREE daily email newsletter.